Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Oral butyrate prodrug in preclinical testing at Vertex

Dec. 13, 1996

Encouraging clinical results with MacroChem Rx for impotence

Dec. 13, 1996

Chugai reports new cholesterol-lowering compounds

Dec. 13, 1996

Novel dual-action compounds described by Abbott

Dec. 12, 1996

New hypolipidemic agents claimed by Janssen

Dec. 12, 1996

Scotia drug shows excellent activity in cancer patients with cachexia

Dec. 11, 1996

Cholesterol-lowering statin approved in first markets

Dec. 11, 1996

New IGF-I variant disclosed by P&U

Dec. 11, 1996

FemPatch approved for marketing in U.S.

Dec. 10, 1996

Benzothiophene compounds for women's health disclosed by Lilly

Dec. 10, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.